Waystar Weighs Sale Amid Falling Valuations in Software Sector

Waystar, a healthcare software provider known for its technology that automates administrative tasks in hospitals and clinics, is exploring strategic options, including a potential sale. This move comes just two years after the company went public in New York. According to seven sources familiar with the situation, Waystar has engaged investment bank Evercore to advise on the process, although discussions remain in preliminary stages.

The company, which operates out of Lehi, Utah, and Louisville, Kentucky, has not publicly commented on the matter. Evercore has also not responded to requests for comment. However, the exploration of a sale indicates that Waystar is seeking to navigate the current challenges in the software market, where its valuation has dropped to approximately $4.8 billion, following a 24% decline in share price this year.

Market Conditions Affecting Valuation

Waystar's initial public offering was buoyed by its positioning as a technology company rather than a traditional healthcare services provider. This strategic branding was intended to attract higher valuations typically associated with tech firms. Investors initially responded positively, driving the company's stock from $20 to a peak of $45 in 2025. However, concerns about the impact of artificial intelligence advancements on software companies have since pressured its stock value.

Morgan Stanley analysts highlighted in a July report that the potential for AI to disrupt current software models has caused investors to reevaluate their positions, contributing to Waystar's current market challenges.

Ownership and Investment Dynamics

Waystar was formed through a 2017 merger between Zirmed and Navicure, two healthcare revenue management companies. It went public in 2024, backed by major investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT is the largest shareholder with a 13% stake, followed by CPPIB with 10% and BlackRock Institutional Trust Company with 8%, according to data from LSEG.

Despite the current exploration of a sale, the outcome is uncertain, and plans could change. Some stakeholders have declined to comment on the situation, while others have not immediately responded to inquiries.

If a sale proceeds, it could signal whether investor interest in software businesses is rebounding, despite broader market volatility. The auction process led by Evercore might offer insights into current investor appetites and the valuation landscape for tech-centric healthcare companies.